Nexeon Medsystems (NXNN) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of Nexeon Medsystems (OTCMKTS:NXNN) from a hold rating to a buy rating in a research note released on Saturday morning.

Separately, Zacks Investment Research downgraded shares of Nexeon Medsystems from a buy rating to a hold rating in a research note on Thursday, August 9th.

NXNN traded down $2.13 on Friday, hitting $4.87. 682 shares of the stock traded hands, compared to its average volume of 334. Nexeon Medsystems has a 52 week low of $3.00 and a 52 week high of $35.00. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.52 and a current ratio of 0.87.



Nexeon Medsystems (OTCMKTS:NXNN) last issued its quarterly earnings results on Monday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.33. Nexeon Medsystems had a negative return on equity of 40.39% and a negative net margin of 7.70%. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.23 million. Equities analysts predict that Nexeon Medsystems will post -1.58 EPS for the current year.

Nexeon Medsystems Company Profile

Nexeon MedSystems Inc, a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets.

Read More: What does earnings per share mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Nexeon Medsystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon Medsystems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply